Ofer 2015 Mol Endocrinol: Revision history

23 January 2019

• curprev 15:0615:06, 23 January 2019‎ Beno Marija talk contribs‎ 2,460 bytes +1‎ No edit summary

13 November 2017

• curprev 15:3115:31, 13 November 2017‎ Kandolf Georg talk contribs‎ 2,459 bytes −1‎ No edit summary

9 November 2016

• curprev 10:4110:41, 9 November 2016‎ Beno Marija talk contribs‎ 2,460 bytes −17‎ No edit summary

8 November 2016

• curprev 09:3809:38, 8 November 2016‎ Beno Marija talk contribs‎ 2,477 bytes −26‎ No edit summary

12 January 2016

• curprev 16:1216:12, 12 January 2016‎ Zhang Feiyuan talk contribs‎ 2,503 bytes −21‎ No edit summary
• curprev 16:1216:12, 12 January 2016‎ Zhang Feiyuan talk contribs‎ 2,524 bytes −10‎ No edit summary

3 January 2016

• curprev 01:1701:17, 3 January 2016‎ Gnaiger Erich talk contribs‎ 2,534 bytes +2‎ No edit summary

7 December 2015

• curprev 17:2417:24, 7 December 2015‎ Kandolf Georg talk contribs‎ 2,532 bytes 0‎ No edit summary

2 November 2015

• curprev 16:0616:06, 2 November 2015‎ Kandolf Georg talk contribs‎ 2,532 bytes +49‎ No edit summary

16 October 2015

• curprev 09:5309:53, 16 October 2015‎ Krumschnabel Gerhard talk contribs‎ 2,483 bytes +2,483‎ Created page with "{{Publication |title=Ofer P, Heidegger I, Eder IE, Schöpf B, Neuwirt H, Geley S, Helmut K, Massoner P (2015) Both IGF1R and INSR knockdown exert anti-tumorigenic effects in pros..."